MSD to acquire the Dundalk site from WuXi Vaccines.

MSD, a pharmaceutical company, agreed to acquire the Dundalk site from WuXi Vaccines, a global contract development and manufacturing organization. Financial terms were not disclosed. “MSD’s manufacturing footprint in Ireland is unparalleled, and I am proud to oversee its continuous expansion, always looking to advance the future of health through innovation and acceleration in the service of people and patients around the world. The acquisition of this WuXi Vaccines site in Dundalk will give us the opportunity to do just that: deliver for people and patients faster, looking at the health challenges of today and tomorrow,” Sanat Chattopadhyay, MSD Executive Vice President and President of Manufacturing Division.